The 70 to 80% savings compared to brand-name Ozempic represents the difference between treatment being available or unavailable for the vast majority of people paying out of pocket
September 30, 2025 MDL Case Count Update The Ozempic / GLP-1 MDL now has 2,914 pending cases
Patients who are suffering from type 2 diabetes mellitus and are already taking Insulin, after additional treatment of Semaglutide developed an increased risk of severe hypoglycemia
Ozempic is a brand-name, FDA-approved pre-filled pen manufactured by Novo Nordisk at fixed doses (0.25, 0.5, 1.0, and 2.0 mg)
The authors concluded, In this real-world, off-label study of use of semaglutide and tirzepatide in OW/OB [overweight/obese] adults with T1D, we observed weight loss of 21% and 9% in the tirzepatide and semaglutide users, respectively, with similar improved glucose control over up to a year of follow-up